Accumulated evidence from clinical and epidemiological studies has shown that high expression of CD133 is associated with poor prognosis in several different types, including brain tumours, colorectal carcinoma, rectal cancer, hepatoma, gastric carcinoma and medulloblastoma [27–30]. The gene discussed is PROM1; the disease is medulloblastoma.